University of Utah
The investigators central hypothesis is that metformin supplementation will be well-tolerated, safe, and provide patients with improved functional and muscle morphology outcomes following intertrochanteric femur fracture. The objectives will be tested in older adults that sustain a hip fracture and are randomized to receive a daily oral dose (1.5g daily) of metformin or a non-active placebo during 4 months of recovery following surgery.
This study team investigates a patient population that undergoes muscle atrophy and falls under the current IND indication of metformin usage to prevent muscle atrophy and enhance muscle growth. The investigators are now proposing to utilize metformin as a novel tool to enhance muscle recovery following a hip fracture in older adults. The investigators currently preparing an IRB protocol in which the investigators plan to perform a pilot study where older adult hip fracture patients are randomized to metformin or placebo. The investigators propose to use metformin to help enhance muscle recove…
Inclusion Criteria: * Age 60y and older. * Displaced hip fracture (femoral neck, intertrochanteric femur, subtrochanteric femur fracture). * Low energy mechanism of injury (ground level fall, etc). * Operative treatment within 72 hours of injury. * Previously ambulatory. Exclusion Criteria: * History of kidney disease or failure (CKD \> stage 4; eGFR \< 45 mL/min/1.73m2). * History of diabetes mellitus (HbA1c \> 6.5). * Associated lower extremity fracture (ipsilateral or contralateral). * Pathologic fracture. * Presence of infection at the fracture site. * History of metabolic bone disease…
Placebo tablets will be dispensed to the participants for 119-days.
Metformin tablets will be dispensed to the participants for 119-days.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.